Outcome of Board Meeting held on August 3, 2026

Q1FY27 results (unaudited): Standalone: Revenue 2.82bn +13% y-y (2.50bn) EBITDA 0.52bn +24% y-y (0.42bn) EBITDA margin 18.4% (16.9%) +150 bps y-y PAT 0.31bn +44% y-y (0.22bn) Consolidated: Revenue 2.87bn +13% y-y (2.55bn) EBITDA 0.52bn +24% y-y (0.42bn) EBITDA margin 18.0% (16.5%) +150 bps y-y PAT 0.31bn +48% y-y (0.21bn) FY26 results (audited): Standalone: Revenue 10.60bn +9% y-y (9.72bn) EBITDA 1.45bn +8% y-y (1.34bn) EBITDA margin 13.7% (13.8%) -10 bps y-y PAT 0.35bn +7% y-y (0.33bn) Consolidated: Revenue 10.81bn +9% y-y (9.93bn) EBITDA 1.47bn +8% y-y (1.36bn) EBITDA margin 13.6% (13.7%) -10 bps y-y PAT 0.35bn +7% y-y (0.33bn) Dividend: None declared Commentary: Board approved expansion of Tower IV adding 200+ beds at flagship Gurugram hospital over ~2 years with investment of Rs 160-180 crore funded by internal accruals and debt.